Comparison
Abacavir Hypersensitivity C5768819 vs 3q26 Microduplication Syndrome C4755319
Clinical comparison between Abacavir Hypersensitivity and 3q26 Microduplication Syndrome for differential diagnosis and treatment planning.
Abacavir Hypersensitivity C5768819
A potentially serious immune reaction to the HIV drug abacavir. Genetic testing is required before starting treatment to identify those at risk of this reaction.
3q26 Microduplication Syndrome C4755319
A genetic condition involving extra genetic material at chromosome 3q26, which can cause developmental delays and other features depending on specific genes involved.
6 comparison axes
Onset
Abacavir Hypersensitivity C5768819
Variable
3q26 Microduplication Syndrome C4755319
0-null
Onset patterns differ
Severity
Abacavir Hypersensitivity C5768819
severe
3q26 Microduplication Syndrome C4755319
moderate
Different severity levels
Chronic
Abacavir Hypersensitivity C5768819
Acute
3q26 Microduplication Syndrome C4755319
Chronic
Differing course
Communicable
Abacavir Hypersensitivity C5768819
No
3q26 Microduplication Syndrome C4755319
No
Different transmission
Body System
Abacavir Hypersensitivity C5768819
immunologic
3q26 Microduplication Syndrome C4755319
congenital
Same/different system
Category
Abacavir Hypersensitivity C5768819
immunologic
3q26 Microduplication Syndrome C4755319
genetic
Different category
Bottom line
abacavir-hypersensitivity-C5768819 and 3q26-microduplication-syndrome-C4755319 differ in severity, chronicity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abacavir Hypersensitivity C5768819 | 3q26 Microduplication Syndrome C4755319 | Discriminating power |
|---|---|---|---|
| Timing of features | Reaction is linked to abacavir exposure and may appear after treatment starts. | Features are congenital and may be recognized from infancy or childhood. | High |
| Developmental pattern | Developmental delay is not a defining feature of the drug reaction. | Developmental delay may occur, depending on genes involved. | Moderate |
| Course | Described as an acute, potentially serious immune reaction. | Described as a chronic genetic condition with variable features. | High |
When to favor each condition
Choose Abacavir Hypersensitivity C5768819 when
Symptoms begin during abacavir treatment
Temporal association supports considering hypersensitivity rather than a congenital syndrome.
High
Pre-treatment genetic risk testing is relevant
Source states testing is required before starting abacavir to identify risk.
High
No lifelong developmental phenotype is described
The supplied concept centers on an immune drug reaction, not congenital features.
Moderate
Choose 3q26 Microduplication Syndrome C4755319 when
Congenital or early developmental concerns
The syndrome involves extra material at chromosome 3q26 and possible developmental delay.
High
No exposure to abacavir
Absence of the implicated drug makes this immune reaction unlikely.
High
Features vary with involved genes
The source explicitly links presentation to the specific duplicated genes.
Moderate
How key tests differ
| Test | Abacavir Hypersensitivity C5768819 | 3q26 Microduplication Syndrome C4755319 | Interpretation |
|---|---|---|---|
| HLA-related risk testing | Required before abacavir to identify people at risk. | Not described as relevant to this syndrome. | A risk result is not itself a diagnosis of hypersensitivity. |
| Chromosomal microarray | Not indicated by the supplied description. | May detect extra material at 3q26. | A genomic finding requires clinician and genetics interpretation. |
| Medication exposure review | Abacavir exposure is central to the concept. | Drug exposure is not part of the syndrome definition. | History helps separate an adverse reaction from a congenital condition. |
Prognosis comparison
Abacavir Hypersensitivity C5768819
- Outcome
- Potentially serious acute reaction; exact outcomes are not established here.
- Factors
- Abacavir exposure and identified genetic risk.
3q26 Microduplication Syndrome C4755319
- Outcome
- Chronic condition with variable developmental and other features.
- Factors
- Specific genes within the duplicated 3q26 region.
Time frame: Acute drug-related versus lifelong congenital course.
Cause, exposure history, genetic findings, and clinical assessment.
Complications comparison
| Complication | Presentation |
|---|---|
| Acute immune reaction | Potentially serious and requires urgent clinical assessment. Not a described feature of the syndrome. Exact warning symptoms and outcomes are not established here. |
| Developmental effects | Not established from the supplied source. Developmental delays and other features may occur. Severity and specific features depend on genes involved. |
| Long-term course | Primarily an acute drug-related event. A chronic congenital condition. Prognosis should be individualized; no mortality data are supplied. |
Patient education highlights
- HighDifferent causes
One is a possible reaction to an HIV medicine; the other is a chromosomal condition present from birth.
- HighAbacavir safety
Do not start, stop, or restart abacavir without the prescribing clinician; risk testing is required beforehand.
- MediumGenetic findings
A 3q26 microduplication needs specialist interpretation because features vary with the genes involved.